Journal of the Neurological Sciences
Volume 287, Issue 1 , Pages 1-6 , 15 December 2009

Multiple sclerosis, osteoporosis, and vitamin D

  • Chrissa Sioka

      Affiliations

    • Department of Nuclear Medicine, University Hospital of Ioannina, Ioannina, Greece
    • ,
  • Athanassios P. Kyritsis

      Affiliations

    • Department of Neurology, University Hospital of Ioannina, Ioannina, Greece
    • Neurosurgical Research Institute, University of Ioannina, Ioannina, Greece
    • Corresponding Author InformationCorresponding author. Dept. of Neurology, University of Ioannina School of Medicine, University Campus, Ioannina 45110, Greece. Tel.: +30 26510 97514; fax: +30 26510 97011.
    • ,
  • Andreas Fotopoulos

      Affiliations

    • Department of Nuclear Medicine, University Hospital of Ioannina, Ioannina, Greece

Received 14 June 2009 ,Revised 25 August 2009 ,Accepted 10 September 2009.

References 

  1. Formica CA, Cosman F, Nieves J, Herbert J, Lindsay R. Reduced bone mass and fat-free mass in women with multiple sclerosis: effects of ambulatory status and glucocorticoid Use. Calcif Tissue Int. 1997;61:129–133
  2. Ozgocmen S, Bulut S, Ilhan N, Gulkesen A, Ardicoglu O, Ozkan Y. Vitamin D deficiency and reduced bone mineral density in multiple sclerosis: effect of ambulatory status and functional capacity. J Bone Miner Metab. 2005;23:309–313
  3. Cosman F, Nieves J, Komar L, Ferrer G, Herbert J, Formica C, et al. Fracture history and bone loss in patients with MS. Neurology. 1998;51:1161–1165
  4. Peterson EW, Cho CC, von Koch L, Finlayson ML. Injurious falls among middle aged and older adults with multiple sclerosis. Arch Phys Med Rehabil. 2008;89:1031–1037
  5. Faulkner MA, Ryan-Haddad AM, Lenz TL, Degner K. Osteoporosis in long-term care residents with multiple sclerosis. Consult Pharm. 2005;20:128–136
  6. Nieves J, Cosman F, Herbert J, Shen V, Lindsay R. High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology. 1994;44:1687–1692
  7. Weinstock-Guttman B, Gallagher E, Baier M, Green L, Feichter J, Patrick K, et al. Risk of bone loss in men with multiple sclerosis. Mult Scler. 2004;10:170–175
  8. Perez Castrillon JL, Cano-del Pozo M, Sanz-Izquierdo S, Velayos-Jimenez J, Dib-Wobakin W. Bone mineral density in patients with multiple sclerosis: The effects of interferon. Rev Neurol. 2003;36:901–903
  9. Shuhaibar M, McKenna MJ, Au-Yeong M, Redmond JM. Favorable effect of immunomodulator therapy on bone mineral density in multiple sclerosis. Ir J Med Sci. 2009;178:43–45
  10. Zorzon M, Zivadinov R, Locatelli L, Giuntini D, Toncic M, Bosco A, et al. Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis. Eur J Neurol. 2005;12:550–556
  11. Stepan JJ, Havrdova E, Tyblova M, Horakova D, Ticha V, Novakova I, et al. Markers of bone remodeling predict rate of bone loss in multiple sclerosis patients treated with low dose glucocorticoids. Clin Chim Acta. 2004;348:147–154
  12. Schwid SR, Goodman AD, Puzas JE, McDermott MP, Mattson DH. Sporadic corticosteroid pulses and osteoporosis in multiple sclerosis. Arch Neurol. 1996;53:753–757
  13. Altintas A, Saruhan-Direskeneli G, Benbir G, Demir M, Purisa S. The role of osteopontin: a shared pathway in the pathogenesis of multiple sclerosis and osteoporosis?. J Neurol Sci. 2009;276:41–44
  14. Tuzun S, Altintas A, Karacan I, Tangurek S, Saip S, Siva A. Bone status in multiple sclerosis: beyond corticosteroids. Mult Scler. 2003;9:600–604
  15. Hawkes CH. Are multiple sclerosis patients risk-takers?. QJM. 2005;98:895–911
  16. Holmoy T, Hestvik AL. Multiple sclerosis: immunopathogenesis and controversies in defining the cause. Curr Opin Infect Dis. 2008;21:271–278
  17. Kampman MT, Brustad M. Vitamin D: a candidate for the environmental effect in multiple sclerosis - observations from Norway. Neuroepidemiology. 2008;30:140–146
  18. Kantarci O, Wingerchuk D. Epidemiology and natural history of multiple sclerosis: new insights. Curr Opin Neurol. 2006;19:248–254
  19. Pugliatti M, Harbo HF, Holmoy T, Kampman MT, Myhr KM, Riise T, et al. Environmental risk factors in multiple sclerosis. Acta Neurol Scand Suppl. 2008;188:34–40
  20. Kampman MT, Wilsgaard T, Mellgren SI. Outdoor activities and diet in childhood and adolescence relate to MS risk above the Arctic Circle. J Neurol. 2007;254:471–477
  21. Norval M, Cullen AP, de Gruijl FR, Longstreth J, Takizawa Y, Lucas RM, et al. The effects on human health from stratospheric ozone depletion and its interactions with climate change. Photochem Photobiol Sci. 2007;6:232–251
  22. Ponsonby AL, McMichael A, van der Mei I. Ultraviolet radiation and autoimmune disease: insights from epidemiological research. Toxicology. 2002;181–182:71–78
  23. Peterlik M, Cross HS. Dysfunction of the vitamin D endocrine system as common cause for multiple malignant and other chronic diseases. Anticancer Res. 2006;26:2581–2588
  24. Adorini L, Penna G. Control of autoimmune diseases by the vitamin D endocrine system. Nat Clin Pract Rheumatol. 2008;4:404–412
  25. Ascherio A, Munger K. Epidemiology of multiple sclerosis: from risk factors to prevention. Semin Neurol. 2008;28:17–28
  26. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann Neurol. 2007;61:504–513
  27. Holick MF. Vitamin D: important for prevention of osteoporosis, cardiovascular heart disease, type 1 diabetes, autoimmune diseases, and some cancers. South Med J. 2005;98:1024–1027
  28. Alpert PT, Shaikh U. The effects of vitamin D deficiency and insufficiency on the endocrine and paracrine systems. Biol Res Nurs. 2007;9:117–129
  29. Kimlin MG. Geographic location and vitamin D synthesis. Mol Aspects Med. 2008;29:453–461
  30. Lips P. Vitamin D physiology. Prog Biophys Mol Biol. 2006;92:4–8
  31. Hayes CE, Nashold FE, Spach KM, Pedersen LB. The immunological functions of the vitamin D endocrine system. Cell Mol Biol (Noisy-le-grand). 2003;49:277–300
  32. Arnson Y, Amital H, Shoenfeld Y. Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis. 2007;66:1137–1142
  33. Mattner F, Smiroldo S, Galbiati F, Muller M, Di Lucia P, Poliani PL, et al. Inhibition of Th1 development and treatment of chronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1, 25-dihydroxyvitamin D(3). Eur J Immunol. 2000;30:498–508
  34. Brown SJ. The role of vitamin D in multiple sclerosis. Ann Pharmacother. 2006;40:1158–1161
  35. Cantorna MT. Vitamin D and multiple sclerosis: an update. Nutr Rev. 2008;66:S135–S138
  36. Grant WB. Epidemiology of disease risks in relation to vitamin D insufficiency. Prog Biophys Mol Biol. 2006;92:65–79
  37. Grant WB, Cross HS, Garland CF, Gorham ED, Moan J, Peterlik M, et al. Estimated benefit of increased vitamin D status in reducing the economic burden of disease in western Europe. Prog Biophys Mol Biol. 2009;
  38. Mark BL, Carson JA. Vitamin D and autoimmune disease–implications for practice from the multiple sclerosis literature. J Am Diet Assoc. 2006;106:418–424
  39. Raghuwanshi A, Joshi SS, Christakos S. Vitamin D and multiple sclerosis. J Cell Biochem. 2008;105:338–343
  40. Pedersen LB, Nashold FE, Spach KM, Hayes CE. 1, 25-dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by inhibiting chemokine synthesis and monocyte trafficking. J Neurosci Res. 2007;85:2480–2490
  41. Muthian G, Raikwar HP, Rajasingh J, Bright JJ. 1, 25 Dihydroxyvitamin-D3 modulates JAK-STAT pathway in IL-12/IFNgamma axis leading to Th1 response in experimental allergic encephalomyelitis. J Neurosci Res. 2006;83:1299–1309
  42. Aranami T, Yamamura T. Th17 Cells and autoimmune encephalomyelitis (EAE/MS). Allergol Intern. 2008;57:115–120
  43. Ramagopalan SV, Maugeri NJ, Handunnetthi L, Lincoln MR, Orton SM, Dyment DA, et al. Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet. 2009;5:e1000369
  44. Meehan TF, DeLuca HF. CD8(+) T cells are not necessary for 1 alpha, 25-dihydroxyvitamin D(3) to suppress experimental autoimmune encephalomyelitis in mice. Proc Natl Acad Sci U S A. 2002;99:5557–5560
  45. Spach KM, Nashold FE, Dittel BN, Hayes CE. IL-10 signaling is essential for 1, 25-dihydroxyvitamin D3-mediated inhibition of experimental autoimmune encephalomyelitis. J Immunol. 2006;177:6030–6037
  46. Spach KM, Pedersen LB, Nashold FE, Kayo T, Yandell BS, Prolla TA, et al. Gene expression analysis suggests that 1, 25-dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by stimulating inflammatory cell apoptosis. Physiol Genomics. 2004;18:141–151
  47. van Etten E, Gysemans C, Branisteanu DD, Verstuyf A, Bouillon R, Overbergh L, et al. Novel insights in the immune function of the vitamin D system: synergism with interferon-beta. J Steroid Biochem Mol Biol. 2007;103:546–551
  48. Smolders J, Peelen E, Thewissen M, Menheere P, Cohen-Tervaert JW, Hupperts R, et al. The relevance of vitamin D receptor gene polymorphisms for vitamin D research in multiple sclerosis. Autoimmun Rev. 2009;
  49. Ban Y, Taniyama M. Vitamin D receptor gene polymorphism is associated with Graves' disease in the Japanese population. J Clin Endocrinol Metab. 2000;85:4639–4643
  50. Fukazawa T, Yabe I, Kikuchi S, Sasaki H, Hamada T, Miyasaka K, et al. Association of vitamin D receptor gene polymorphism with multiple sclerosis in Japanese. J Neurol Sci. 1999;166:47–52
  51. Dickinson J, Perera D, van der Mei A, Ponsonby AL, Polanowski A, Thomson R, et al. Past environmental sun exposure and risk of multiple sclerosis: a role for the Cdx-2 Vitamin D receptor variant in this interaction. Mult Scler. 2009;15:563–570
  52. Mamutse G, Woolmore J, Pye E, Partridge J, Boggild M, Young C, et al. Vitamin D receptor gene polymorphism is associated with reduced disability in multiple sclerosis. Mult Scler. 2008;14:1280–1283
  53. Partridge JM, Weatherby SJ, Woolmore JA, Highland DJ, Fryer AA, Mann CL, et al. Susceptibility and outcome in MS: associations with polymorphisms in pigmentation-related genes. Neurology. 2004;62:2323–2325
  54. Smolders J, Damoiseaux J, Menheere P, Tervaert JW, Hupperts R. Fok-I vitamin D receptor gene polymorphism (rs10735810) and vitamin D metabolism in multiple sclerosis. J Neuroimmunol. 2009;207:117–121
  55. Niino M, Fukazawa T, Yabe I, Kikuchi S, Sasaki H, Tashiro K. Vitamin D receptor gene polymorphism in multiple sclerosis and the association with HLA class II alleles. J Neurol Sci. 2000;177:65–71
  56. Dwyer T, van der Mei I, Ponsonby AL, Taylor BV, Stankovich J, McKay JD, et al. Melanocortin 1 receptor genotype, past environmental sun exposure, and risk of multiple sclerosis. Neurology. 2008;71:583–589
  57. Speeckaert M, Huang G, Delanghe JR, Taes YE. Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clin Chim Acta. 2006;372:33–42
  58. Niino M, Kikuchi S, Fukazawa T, Yabe I, Tashiro K. No association of vitamin D-binding protein gene polymorphisms in Japanese patients with MS. J Neuroimmunol. 2002;127:177–179
  59. Qin Z, Qin Y, Liu S. Alteration of DBP levels in CSF of patients with MS by proteomics analysis. Cell Mol Neurobiol. 2009;29:203–210
  60. Niino M, Fukazawa T, Kikuchi S, Sasaki H. Therapeutic potential of vitamin D for multiple sclerosis. Curr Med Chem. 2008;15:499–505
  61. Munger KL, Zhang SM, O'Reilly E, Hernan MA, Olek MJ, Willett WC, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology. 2004;62:60–65
  62. Nashold FE, Miller DJ, Hayes CE. 1, 25-dihydroxyvitamin D3 treatment decreases macrophage accumulation in the CNS of mice with experimental autoimmune encephalomyelitis. J Neuroimmunol. 2000;103:171–179
  63. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA. 2006;296:2832–2838
  64. Barnes MS, Bonham MP, Robson PJ, Strain JJ, Lowe-Strong AS, Eaton-Evans J, et al. Assessment of 25-hydroxyvitamin D and 1, 25-dihydroxyvitamin D3 concentrations in male and female multiple sclerosis patients and control volunteers. Mult Scler. 2007;13:670–672
  65. Correale J, Ysrraelit MC, Gaitan MI. Immunomodulatory effects of Vitamin D in multiple sclerosis. Brain. 2009;132:1146–1160
  66. Hiremath G, Cettomai D, Baynes M, Ratchford J, Newsome S, Harrison D, et al. Vitamin D status and effect of low-dose cholecalciferol and high-dose ergocalciferol supplementation in multiple sclerosis. Mult Scler. 2009;
  67. Soilu-Hanninen M, Airas L, Mononen I, Heikkila A, Viljanen M, Hanninen A. 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult Scler. 2005;11:266–271
  68. Chatfield SM, Brand C, Ebeling PR, Russell DM. Vitamin D deficiency in general medical inpatients in summer and winter. Intern Med J. 2007;37:377–382
  69. Tremlett H, van der Mei IA, Pittas F, Blizzard L, Paley G, Mesaros D, et al. Monthly ambient sunlight, infections and relapse rates in multiple sclerosis. Neuroepidemiology. 2008;31:271–279
  70. van der Mei IA, Ponsonby AL, Dwyer T, Blizzard L, Taylor BV, Kilpatrick T, et al. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol. 2007;254:581–590
  71. Soilu-Hanninen M, Laaksonen M, Laitinen I, Eralinna JP, Lilius EM, Mononen I. A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2008;79:152–157
  72. Cannell JJ, Hollis BW. Use of vitamin D in clinical practice. Altern Med Rev. 2008;13:6–20
  73. Namaka M, Crook A, Doupe A, Kler K, Vasconcelos M, Klowak M, et al. Examining the evidence: complementary adjunctive therapies for multiple sclerosis. Neurol Res. 2008;30:710–719
  74. Vieth R. Why the optimal requirement for Vitamin D3 is probably much higher than what is officially recommended for adults. J Steroid Biochem Mol Biol. 2004;89–90:575–579
  75. Zittermann A. Vitamin D in preventive medicine: are we ignoring the evidence?. Br J Nutr. 2003;89:552–572
  76. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr. 1999;69:842–856
  77. Wingerchuk DM, Lesaux J, Rice GP, Kremenchutzky M, Ebers GC. A pilot study of oral calcitriol (1, 25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2005;76:1294–1296
  78. Kimball SM, Ursell MR, O'Connor P, Vieth R. Safety of vitamin D3 in adults with multiple sclerosis. Am J Clin Nutr. 2007;86:645–651
  79. Tajouri L, Ovcaric M, Curtain R, Johnson MP, Griffiths LR, Csurhes P, et al. Variation in the vitamin D receptor gene is associated with multiple sclerosis in an Australian population. J Neurogenet. 2005;19:25–38
  80. Kragt J, van Amerongen B, Killestein J, Dijkstra C, Uitdehaag B, Polman C, et al. Higher levels of 25-hydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women. Mult Scler. 2009;15:9–15

PII: S0022-510X(09)00854-5

doi: 10.1016/j.jns.2009.09.012

Journal of the Neurological Sciences
Volume 287, Issue 1 , Pages 1-6 , 15 December 2009

Article Tools